- Home
- EYPT vs PSEC Comparison
EYPT vs PSEC Comparison
Compare EYPT & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | PSEC |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance/Investors Services |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2005 | 2004 |
Fundamental Metrics
Financial Performance| Metric | EYPT | PSEC |
|---|---|---|
| Price | $15.19 | $2.74 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $28.75 | $2.50 |
| AVG Volume (30 Days) | 907.6K | ★ 4.7M |
| Earning Date | 03-04-2026 | 02-06-2026 |
| Dividend Yield | N/A | ★ 18.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $42,339,000.00 | ★ $680,752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $2.45 |
| 52 Week High | $19.11 | $4.47 |
Technical Indicators
Market Signals| Indicator | EYPT | PSEC |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 48.77 |
| Support Level | $14.62 | $2.76 |
| Resistance Level | $16.73 | $2.92 |
| Average True Range (ATR) | 1.03 | 0.09 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 21.30 | 13.30 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About PSEC Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.